Regdanvimab improves disease mortality and morbidity in patients with COVID-19: a meta-analysis

Regdanvimab improves disease mortality and morbidity in patients with COVID-19: a meta-analysis

•All studies compared the impact of regdanvimab on clinical outcomes•A total of 7 articles comprising 3333 adult patients with COVID-19 were included in the analysis•Outcomes suggested that regdanvimab administration reduces the risk of disease aggravation and death among COVID-19 patients.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of infection 2022-10, Vol.85 (4), p.e122-e124
Hauptverfasser: Yang, Mingyang, Li, Anthony, Jiang, Lihai, Wang, Yushu, Tran, Carolyn, Ao, Guangyu
Format: Artikel
Sprache:eng
Schlagworte:
Antibodies, Monoclonal, Humanized
Antibodies, Neutralizing
COVID-19
COVID-19 Drug Treatment
Humans
Immunoglobulin G
Letter to the Editor
Morbidity
Mortality
Regdanvimab
SARS-CoV-2
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•All studies compared the impact of regdanvimab on clinical outcomes•A total of 7 articles comprising 3333 adult patients with COVID-19 were included in the analysis•Outcomes suggested that regdanvimab administration reduces the risk of disease aggravation and death among COVID-19 patients.
ISSN:0163-4453
1532-2742
DOI:10.1016/j.jinf.2022.05.044